QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

QuidelOrtho Corporation

Virbac offers veterinarians, farmers, and pet owners a range of products and services focused on animal health, covering various species and diseases, self-described as contributing to the future of animal health.

Virbac

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

West Pharmaceutical Services, Inc.

QuidelOrtho provides diagnostic solutions and testing capabilities in healthcare, aiming to transform diagnostic data into actionable intelligence.

Metric
Company Name	QuidelOrtho Corporation	Virbac	West Pharmaceutical Services, Inc.
Symbol	QDEL		WST
MSH ID	COM:QUIDELORTHO	COM:VIRBAC	COM:WESTPHARMA
Market	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare
Industry	Medical - Instruments & Supplies	Veterinary	Medical - Instruments & Supplies
Country	US	FR	US
Stage
Employee Count	7.10K		10.60K
Website	quidelortho.com	virbac.com	westpharma.com
LinkedIn
Founders

Metric
Market Cap	2.01B	23.41B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.99B	2.95B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.28B	1.13B
EBITDA	703.50M	875.70M
Operating Income	246.30M	676M
Net Income	-10.10M	593.40M
EPS	-0.15	7.98
Diluted EPS	-0.15	7.88
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.48	0.38
Operating Profit Margin	0.05	0.23
EBITDA Margin	0.24	0.30
Net Profit Margin	-0.00	0.20
Return on Equity	-0.00	0.21
Return on Assets	-0.00	0.16
Return on Capital Employed	0.02	0.22

COM:QUIDELORTHO

QuidelOrtho

Last Close

37.89

22/11 21:00

Market Cap

2.01B

Beta: -

Volume Today

4.30M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	344.14	52.81
P/B Ratio	0.91	10.30
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.10	9.76
EV Multiple	1.77	34.90

Metric
Days Sales Outstanding	38.73	64.74
Days Payables Outstanding	59.21	44.24
Days Inventory Outstanding	134.78	87.15
Operating Cycle	197.80	150.56
Cash Conversion Cycle	145.07	104.66
Asset Turnover	0.43	0.82

Metric
Operating Cash Flow	280.20M	776.50M
Free Cash Flow	70.90M	414.50M
Cash Flow to Debt	0.11	3.31
Operating Cash Flow/Sales	0.09	0.26
Free Cash Flow Yield	0.04	0.01

Metric
Cash & Equivalents	118.90M	853.90M
Accounts Receivable	160M	4M
Inventory	577.80M	434.70M
Goodwill	2.49B	108.50M
Debt to Capitalization	0.46	0.10
Debt to Assets	0.31	0.08
Current Ratio	1.59	3.70
Quick Ratio	0.81	2.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.01
R&D to Revenue	0.08	0.02
SG&A to Revenue	0.01